IMEX   05356
INSTITUTO DE MEDICINA EXPERIMENTAL
Unidad Ejecutora - UE
congresos y reuniones científicas
Título:
HAIRY CELL LEUKEMIA: IN VITRO SENSITIVITY TO VENETOCLAX AND ROLE OF THE MICROENVIRONMET
Autor/es:
COLADO, ANA; SARAPURA MARTÍNEZ, VALERIA; FERNÁNDEZ GRECCO, HORACIO; GAMBERALE, ROMINA; ELÍAS, ESTEBAN E.; AMONDARAIN, MIKELE; CORDINI, GREGORIO; GIORDANO, MIRTA; VEREERTBRUGGHEN, ALEXIA; VERGARA RUBIO, MARICEF; BEZARES, RAIMUNDO FERNANDO; BORGE, MERCEDES; MORANDE, PABLO
Lugar:
San Miguel de Tucuman
Reunión:
Congreso; LVII Reunión Anual de la Sociedad Argentina de Inmunología; 2019
Resumen:
Background: Hairy cell leukemia (HCL) is a neoplastic disease of low incidence that affects the elderly and is characterized by the accumulation of tumor B cells in spleen, bone marrow and peripheral blood. Pancytopenia represents the most frequent symptom and although treatment with purine analogs shows a partial response, it remains incurable. Venetoclax is a Bcl-2 inhibitor successfully used in chronic lymphocytic leukemia (CLL). Given that HCL cells express Bcl-2, our aim was to evaluate venetoclax in vitro, as a potential therapy for HCL.Methods: Peripheral blood mononuclear cells from HCL patients were incubated with venetoclax, and after 24 hs apoptosis was evaluated by flow cytometry using Annexin V. Because microenvironment signals induce resistance to venetoclax in CLL, we also evaluated the effect of the drug in HCL cells pre-incubated with agonists for TLR-9 (CpG), or TLR-2 (PAM3), or anti-CD3-activated T cells.Results: Venetoclax increased the percentages of AnnexinV+ HCL cells at clinically relevant concentrations of 0.1 and 1 μM (n=5, p